Form 4: Glaukos Corp Executive Joseph Gilliam Reports Stock Transactions
SEC Form 4 Filing
Joseph Gilliam, President & COO of Glaukos Corporation, reports acquisition of shares and stock options due to performance target achievements and new grants.
Summary
- On March 14, 2024, Joseph Gilliam, President & COO of Glaukos Corporation, reported transactions involving Glaukos Corp [GKOS] common stock and stock options.
- Gilliam acquired 3,886 shares of common stock related to previously granted restricted stock units, with vesting occurring in March and December 2024.
- He also acquired 8,743 restricted stock units that vest over a four-year period.
- Additionally, Gilliam acquired options to purchase 3,660 shares of common stock related to a previously granted option, vesting in March and December 2024.
- He was also granted an option to purchase 15,161 shares of common stock on March 14, 2024, which vests over four years.
- Following these transactions, Gilliam beneficially owns 111,017 shares of common stock and 58,757 stock options.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing simply reports transactions related to executive compensation. The vesting of shares based on performance targets suggests positive company performance, but the filing itself is not inherently positive or negative.
Positives
- The vesting of restricted stock units and stock options indicates the achievement of certain operational targets, which could be viewed positively.
- The grant of new stock options to the President & COO aligns his interests with those of the shareholders.
Future Outlook
The document does not contain explicit forward-looking statements, but the vesting schedules of the restricted stock units and stock options extend into the future.
Industry Context
This filing is a routine disclosure of insider transactions and provides insight into executive compensation structures within Glaukos, a company in the ophthalmic medical technology sector. Such filings are common and expected.
Comparison to Industry Standards
- Stock option and restricted stock unit grants are standard compensation practices in the medical technology industry, used to incentivize executives and align their interests with shareholders.
- Vesting schedules tied to performance metrics are also common, ensuring that executives are rewarded for achieving specific company goals.
- Companies like Alcon, Johnson & Johnson (Vision Care), and Bausch + Lomb also utilize similar compensation strategies for their executives.
Stakeholder Impact
- Shareholders may view the vesting of shares and options positively, as it indicates the achievement of company goals.
- Employees may be motivated by the fact that executive compensation is tied to company performance.
Key Dates
| Date | Description |
|---|---|
| 03/18/2021 | Date of original grant of restricted stock units, a portion of which vested on 03/14/2024. |
| 03/24/2022 | Date of original grant of stock options, a portion of which vested on 03/14/2024. |
| 03/14/2024 | Date of transaction and determination by the Compensation Committee that operational targets were achieved. |
| 03/18/2024 | Date of signature of the Form 4 filing. |
| 03/24/2032 | Expiration date of a portion of the stock options. |
| 03/14/2034 | Expiration date of stock options granted on 03/14/2024. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.